Integrated Filing — IndAS



General information about company
Scrip Code 524404
NSE Symbol MARKSANS
MSEI Symbol NOTLISTED
ISIN INE750C01026
Name of company Marksans Pharma Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2025
Date of end of financial year 31-Mar-2026
Date of board meeting when results were approved 12-Aug-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 24-Jul-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Single segment
Description of single segment Pharmaceutical Formulation
Start date and time of board meeting 12-Aug-2025   11:45:00
End date and time of board meeting 12-Aug-2025   13:10:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 6199890000
Other income 56410000
Total income 6256300000
2 Expenses
(a) Cost of materials consumed 1926940000
(b) Purchases of stock-in-trade 1715470000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -1024290000
(d) Employee benefit expense 983850000
(e) Finance costs 60650000
(f) Depreciation, depletion and amortisation expense 231010000
(f) Other Expenses
1 Other Expenses 1596690000 1596690000
Total other expenses 1596690000
Total expenses 5490320000
3 Total profit before exceptional items and tax 765980000
4 Exceptional items 0
5 Total profit before tax 765980000
6 Tax expense
7 Current tax 196080000
8 Deferred tax -12120000
9 Total tax expenses 183960000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0
11 Net Profit Loss for the period from continuing operations 582020000
12 Profit (loss) from discontinued operations before tax 0
13 Tax expense of discontinued operations 0
14 Net profit (loss) from discontinued operation after tax 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0
16 Total profit (loss) for period 582020000
17 Other comprehensive income net of taxes 665290000
18 Total Comprehensive Income for the period 1247310000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 583170000
Total profit or loss, attributable to non-controlling interests -1150000
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 1236200000
Total comprehensive income for the period attributable to owners of parent non-controlling interests 11110000
21 Details of equity share capital
Paid-up equity share capital 453160000
Face value of equity share capital 1
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 1.29
Diluted earnings (loss) per share from continuing operations 1.29
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0
Diluted earnings (loss) per share from discontinued operations 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 1.29
Diluted earnings (loss) per share from continuing and discontinued operations 1.29
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) The consolidated unaudited financial results for the quarter ended 30 June 2025 of Marksans Pharma Limited n('the Company' or 'the holding company') and its subsidiaries (collectively referred as 'the Group') were nreviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 12 nAugust 2025. The Statutory Auditors of the Company have carried out limited review on the above results in nterms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('the nRegulation'), as amended and expressed an unmodified conclusion. n nThe consolidated unaudited financial results of the Company have been prepared in accordance with the nrecognition and measurement principles laid down in the Indian Accounting Standard 34 ‘Interim Financial nReporting’, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued nthereunder and other recognised accounting principles generally accepted in India and in terms of the nRegulation. n nThe figures for the quarter ended 31 March 2025 represent the derived figures between the audited figures in nrespect of full financial year ended 31 March 2025 and the unaudited published year-to-date figures up to 31 nDecember 2024, being the date of the end of third quarter of the financial year, which were subjected to a nlimited review by the statutory auditor of the Company. n nThe Group's activities comprise of manufacturing pharmaceutical formulation and trading in pharmaceutical nproducts. The Group has only one reportable segment namely 'Pharmaceuticals' as per Ind AS 108 on n'Operating Segments'. n nOther income, net includes net loss on foreign exchange differences amounting to 37.73 million for the quarter nended 30 June 2025 31 March 2025 net gain of 25.80 million 30 June 2024: net gain of 26.11 million; year nended 31 March 2025 net gain of 194.80 million. n nThe above consolidated unaudited financials results are available on the Company's website nwww.marksanspharma.com and stock exchanges websites , BSE www.bseindia.com and NSE nwww.nseindia.com, where the shares of the Company are listed.



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2025
Date of end of reporting period 30-Jun-2025
Whether accounts are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurements of the net defined benefit liabilities/assets -1010000 -1010000
Total Amount of items that will not be reclassified to profit and loss -1010000
2 Income tax relating to items that will not be reclassified to profit or loss -250000
3 Amount of items that will be reclassified to profit and loss
1 Foreign currency translation reserve 666050000 666050000
Total Amount of items that will be reclassified to profit and loss 666050000
4 Income tax relating to items that will be reclassified to profit or loss 0
5 Total Other comprehensive income 665290000





Details of Impact of Audit Qualification
Whether results are audited or unaudited Unaudited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 M S K A & Associatesn Yes 31-Jul-2027